Comparative Pharmacology
Head-to-head clinical analysis: NEXIUM IV versus PRILOSEC OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXIUM IV versus PRILOSEC OTC.
NEXIUM IV vs PRILOSEC OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Esomeprazole is the S-isomer of omeprazole, which is concentrated in the acidic environment of parietal cells and converted to the active sulfenamide form that binds covalently with the proton pump, leading to irreversible inhibition.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
20-40 mg intravenously once daily; for GERD with erosive esophagitis: 20-40 mg once daily; for Zollinger-Ellison syndrome: 80 mg IV every 12 hours, adjust based on acid output.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults. In patients with hepatic impairment (Child-Pugh Class A, B, or C), half-life may be prolonged up to 2.9-8 hours.
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Renal (approx. 80% as inactive metabolites), fecal (approx. 20% as metabolites and parent drug). Less than 1% excreted unchanged in urine.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor